Free Trial

Dogwood Therapeutics Q4 2024 Earnings Report

Dogwood Therapeutics logo
$4.25 +0.07 (+1.67%)
As of 04/4/2025 04:00 PM Eastern

Dogwood Therapeutics EPS Results

Actual EPS
-$6.29
Consensus EPS
-$1.49
Beat/Miss
Missed by -$4.80
One Year Ago EPS
N/A

Dogwood Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dogwood Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Dogwood Therapeutics Earnings Headlines

Dogwood regains Nasdaq compliance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Dogwood doses first patient in Phase 2b trial of Halneuron
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX) is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

View Dogwood Therapeutics Profile

More Earnings Resources from MarketBeat